Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
LYRA 
Lyra Therapeutics Inc (LYRA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: LYRA (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
4 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $23
1 Year Target Price $23
| 0 | Strong Buy |
| 0 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 12.3% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 12.07M USD | Price to earnings Ratio - | 1Y Target Price 23 |
Price to earnings Ratio - | 1Y Target Price 23 | ||
Volume (30-day avg) 4 | Beta 0.01 | 52 Weeks Range 3.81 - 34.00 | Updated Date 06/30/2025 |
52 Weeks Range 3.81 - 34.00 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -60.5 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -4347.54% |
Management Effectiveness
Return on Assets (TTM) -28.54% | Return on Equity (TTM) -195.46% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 13887058 | Price to Sales(TTM) 10.19 |
Enterprise Value 13887058 | Price to Sales(TTM) 10.19 | ||
Enterprise Value to Revenue 11.72 | Enterprise Value to EBITDA 0.66 | Shares Outstanding 1325340 | Shares Floating 940279 |
Shares Outstanding 1325340 | Shares Floating 940279 | ||
Percent Insiders 0.83 | Percent Institutions 48.61 |
Analyst Ratings
Rating 2 | Target Price 23 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 4 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Lyra Therapeutics Inc
Company Overview
History and Background
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company focused on developing innovative ENT (ear, nose, and throat) therapies. Founded in 2003. Their focus has been on developing a novel drug delivery platform for chronic rhinosinusitis.
Core Business Areas
- ENT Therapies: Developing and commercializing bioresorbable nasal implants for the treatment of chronic rhinosinusitis (CRS).
Leadership and Structure
The leadership team includes experienced professionals in pharmaceuticals, drug delivery, and ENT. Information on the exact organizational structure and board composition is subject to change and should be sourced directly from the company's investor relations page.
Top Products and Market Share
Key Offerings
- LYRA-379: LYRA-379 is a bioresorbable nasal implant designed to deliver mometasone furoate, a corticosteroid, directly to the sinuses for the treatment of CRS. LYRA-379 had a setback after a Phase 3 study failed to meet its primary endpoint. Competitors include traditional steroid sprays, surgery, and other emerging drug delivery systems from companies like Intersect ENT (acquired by Medtronic).
- LYRA-380: A follow-up formulation to LYRA-379. Market share is currently 0 as it is undergoing clinical trials. Competitors include traditional steroid sprays, surgery, and other emerging drug delivery systems from companies like Intersect ENT (acquired by Medtronic).
Market Dynamics
Industry Overview
The ENT therapeutics market is growing, driven by the increasing prevalence of chronic rhinosinusitis and the demand for effective, less invasive treatment options. This market includes nasal sprays, biologics, and surgical procedures.
Positioning
Lyra Therapeutics aims to position itself as a leader in drug delivery for ENT conditions, offering a localized and sustained release of medication. The success depends on the clinical outcomes and regulatory approval of their lead candidates.
Total Addressable Market (TAM)
The TAM for CRS therapeutics is estimated to be several billion dollars globally. Lyra's position depends on successful commercialization and acceptance of its drug delivery platform.
Upturn SWOT Analysis
Strengths
- Novel drug delivery technology
- Potential for localized and sustained drug release
- Focus on unmet needs in ENT
Weaknesses
- Clinical trial setbacks (LYRA-379)
- Dependence on regulatory approval
- Limited commercialized products
Opportunities
- Expanding applications of drug delivery platform
- Partnerships with larger pharmaceutical companies
- Addressing other ENT conditions
Threats
- Competition from established therapies
- Regulatory hurdles
- Clinical trial risks
Competitors and Market Share
Key Competitors
- MDT
- SNY
Competitive Landscape
Lyra Therapeutics faces competition from established pharmaceutical companies and medical device manufacturers. Its advantage lies in its novel drug delivery platform.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by progress in clinical trials and development of the drug delivery platform.
Future Projections: Future growth is contingent on successful clinical trials, regulatory approvals, and commercialization of its products.
Recent Initiatives: Recent initiatives include advancing clinical trials for LYRA-380.
Summary
Lyra Therapeutics is a high-risk, high-reward clinical-stage company. Their innovative drug delivery platform shows promise, but they face significant hurdles in clinical trials and regulatory approval. The company's financial stability depends on securing additional funding or partnerships. The negative LYRA-379 Phase 3 results increases its risk. Long term prospects are predicated on LYRA-380's approval.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings (10-K, 10-Q)
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual research and consultation with a financial professional. Market share data is estimated and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lyra Therapeutics Inc
Exchange NASDAQ | Headquaters Watertown, MA, United States | ||
IPO Launch date 2020-05-01 | CEO, President & Director Dr. Maria Palasis Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 30 | Website https://lyratherapeutics.com |
Full time employees 30 | Website https://lyratherapeutics.com | ||
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.